Trial Outcomes & Findings for Reducing Intracranial atheroSclErosis With Repatha (NCT NCT04573777)

NCT ID: NCT04573777

Last Updated: 2023-03-15

Results Overview

Measured on ToF MRA, CE-MRA, T1 Dante

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

10 participants

Primary outcome timeframe

1.5 years

Results posted on

2023-03-15

Participant Flow

Participant milestones

Participant milestones
Measure	Intervention Repatha Repatha: 140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
Overall Study STARTED	10
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	10

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Reducing Intracranial atheroSclErosis With Repatha

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Intervention Repatha n=10 Participants Repatha: 140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
Age, Categorical <=18 years	0 Participants n=93 Participants
Age, Categorical Between 18 and 65 years	5 Participants n=93 Participants
Age, Categorical >=65 years	5 Participants n=93 Participants
Sex: Female, Male Female	5 Participants n=93 Participants
Sex: Female, Male Male	5 Participants n=93 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=93 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	9 Participants n=93 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants
Race (NIH/OMB) Asian	2 Participants n=93 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants
Race (NIH/OMB) Black or African American	1 Participants n=93 Participants
Race (NIH/OMB) White	7 Participants n=93 Participants
Race (NIH/OMB) More than one race	0 Participants n=93 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants
Region of Enrollment United States	10 Participants n=93 Participants

PRIMARY outcome

Timeframe: 1.5 years

Population: Outcome data were not collected due to early termination

Measured on ToF MRA, CE-MRA, T1 Dante

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 1.5 years

Population: Study funding was terminated before reaching the analysis phase of the study. No participants made it to 1.5 years. Outcome data were not collected due to early termination

Measured on ToF MRA, CE-MRA, T1/T2/PD Dante

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 1.5 years

Population: Study funding was terminated before reaching the analysis phase of the study. No participants made it to 1.5 years

Adjudicated

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: 1.5 years

Population: Study funding was terminated before reaching the analysis phase of the study. No participants made it to 1.5 years

Adjudicated

Outcome measures

Outcome data not reported

Adverse Events

Intervention Repatha

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

David Liebeskind

UCaliforniaLA

Phone: ‭(310) 963-5539‬

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place